Stuart Seropian, MD

Associate Professor of Medicine (Hematology)

Research Departments & Organizations

Internal Medicine: Hematology

Yale Cancer Center: Cancer Immunology

Office of Cooperative Research

Research Interests

Bone Marrow Transplantation; Clinical Trials, Phase III as Topic; Hematologic Diseases; Hematopoietic Stem Cells; Hodgkin Disease; Leukemia; Lymphocytes; Lymphoma; Lymphoma, Non-Hodgkin; Plasma Cells

Clinical Trials

Conditions Study Title
Non-Hodgkin's Lymphoma A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas
Phase I A Phase 1 Study of an Autologous ACTR T Cell Product in Combination With Trastuzumab, a Monoclonal Antibody, in Subjects With HER2-Positive Advanced Malignancies
Non-Hodgkin's Lymphoma Pilot Phase 2 Study of Intratumoral G100 in Patients With Cutaneous T Cell Lymphoma
Leukemia, other A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/ITD AML
Lymphoid Leukemia A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Multiple Myeloma Phase I Safety and Feasibility Study of Autologous CD8+ T-cells Transiently Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen in Patients With Multiple Myeloma
Non-Hodgkin's Lymphoma Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Multiple Myeloma A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis
Non-Hodgkin's Lymphoma An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Multiple Myeloma Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma with Carfilzomib Lenalidomide Dexamethasone (CRD)
Non-Hodgkin's Lymphoma A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma
Hodgkin's Lymphoma, Lymphoid Leukemia A Phase Ia/Ib Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, DTRM-505 and DTRM-555, in Patients With Chronic Lymphocytic Leukemia or Other B-cell Lymphomas
Multiple Myeloma Safety Study of SGN-CD48A in Patients With Multiple Myeloma
Non-Hodgkin's Lymphoma A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma A Phase I Trial of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)
Non-Hodgkin's Lymphoma A Phase Ib/II Study Evaluating the Safety and Efficacy of Obinutuzumab in Combination With Polatuzumab Vedotin and Venetoclax in Patients With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Lymphoid Leukemia A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Phase I An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Mycosis Fungoides, Phase I A Phase I Dose-ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 Following Local Intratumoral and Subcutaneous Injection in Patients With Cutaneous T Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-type

Edit this profile

Contact Info

Stuart Seropian, MD
Mailing Address
Yale Cancer CenterPO Box 208028
333 Cedar Street, TMP 3

New Haven, CT 06520-8028